Trial Profile
An Open-label, Multi-Centre, Non-Randomised Extension Study to Assess the Ability to Maintain a Stable Haemoglobin and to Assess Safety of Iron Isomaltoside 1000 (Monofer) in Subjects With Inflammatory Bowel Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2019
Price :
$35
*
At a glance
- Drugs Ferric derisomaltose (Primary)
- Indications Inflammatory bowel diseases; Iron deficiency anaemia
- Focus Registrational; Therapeutic Use
- Sponsors Pharmacosmos
- 03 Dec 2013 New trial record
- 01 Nov 2011 Recruitment completed, according to results published in the Scandinavian Journal of Gastroenterology.